I-Mab
NASDAQ:IMAB
I-Mab
Cost of Revenue
I-Mab
Cost of Revenue Peer Comparison
Competitive Cost of Revenue Analysis
Latest Figures & CAGR of Competitors
Company | Cost of Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
I-Mab
NASDAQ:IMAB
|
Cost of Revenue
¥0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Beigene Ltd
HKEX:6160
|
Cost of Revenue
-¥2.7B
|
CAGR 3-Years
-77%
|
CAGR 5-Years
-70%
|
CAGR 10-Years
N/A
|
|
Innovent Biologics Inc
HKEX:1801
|
Cost of Revenue
-¥1.1B
|
CAGR 3-Years
-43%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
|
Cost of Revenue
-¥992.7m
|
CAGR 3-Years
-28%
|
CAGR 5-Years
-29%
|
CAGR 10-Years
N/A
|
|
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
|
Cost of Revenue
-¥39.6B
|
CAGR 3-Years
-58%
|
CAGR 5-Years
-63%
|
CAGR 10-Years
-63%
|
|
Imeik Technology Development Co Ltd
SZSE:300896
|
Cost of Revenue
-¥99.9m
|
CAGR 3-Years
-34%
|
CAGR 5-Years
-27%
|
CAGR 10-Years
N/A
|
See Also
What is I-Mab's Cost of Revenue?
Cost of Revenue
0
CNY
Based on the financial report for Dec 31, 2023, I-Mab's Cost of Revenue amounts to 0 CNY.